- Open Access
Determining the clinical importance of treatment benefits for interventions for painful orthopedic conditions
Journal of Orthopaedic Surgery and Research volume 10, Article number: 24 (2015)
The overarching goals of treatments for orthopedic conditions are generally to improve or restore function and alleviate pain. Results of clinical trials are generally used to determine whether a treatment is efficacious; however, a statistically significant improvement may not actually be clinically important, i.e., meaningful to the patient. To determine whether an intervention has produced clinically important benefits requires a two-step process: first, determining the magnitude of change considered clinically important for a particular measure in the relevant population and, second, applying this yardstick to a patient’s data to determine whether s/he has benefited from treatment. Several metrics have been devised to quantify clinically important differences, including the minimum clinically important difference (MCID) and clinically important difference (CID). Herein, we review the methods to generate the MCID and other metrics and their use and interpretation in clinical trials and practice. We particularly highlight the many pitfalls associated with the generation and utilization of these metrics that can impair their correct use. These pitfalls include the fact that different pain measures yield different MCIDs, that efficacy in clinical trials is impacted by various factors (population characteristics, trial design), that the MCID value is impacted by the method used to calculate it (anchor, distribution), by the type of anchor chosen and by the definition (threshold) of improvement. The MCID is also dependent on the population characteristics such as disease type and severity, sex, age, etc. For appropriate use, the MCID should be applied to changes in individual subjects, not to group changes. The MCID and CID are useful tools to define general guidelines to determine whether a treatment produces clinically meaningful effects. However, the many pitfalls associated with these metrics require a detailed understanding of the methods to calculate them and their context of use. Orthopedic surgeons that will use these metrics need to carefully understand them and be aware of their pitfalls.
Musculoskeletal conditions are often associated with reduced function and pain. In most common orthopedic conditions, patients and clinicians determine the success of treatment based on two main outcomes: pain reduction and functional improvement . Whether a treatment is efficacious is determined by reviewing the results of randomized controlled trials (RCTs). The primary thrust of RCTs is to demonstrate a statistically significant difference in outcome between treatment groups. Statistical significance, however, does not necessarily imply clinical significance, or clinical importance, i.e., whether the observed improvement is meaningful to the patient [2-5]. Very small treatment effects, too small to be meaningful to patients, will be statistically significant if the sample sizes are large enough. Treatments that produce large and clinically important benefits may fail to achieve statistical significance if the sample size was too small. To this end, clinical researchers have introduced a series of metrics to determine whether improvements after treatment are clinically important .
Determining whether a treatment effect is clinically significant is paramount for a variety of stakeholders in the orthopedic community, including committees that develop treatment guidelines and formularies, make regulatory decisions, set market access and reimbursement policies, conduct systematic reviews, and practicing orthopedists who need to make informed decisions regarding patient treatments. Errors in determination of clinical significance of interventions for orthopedic conditions may have high consequences. These stakeholders bear a responsibility to understand how clinical importance is determined and ensure that decisions based on estimates of clinical importance are based on appropriate methods.
Other aspects of treatment should be considered in the choice of one orthopedic intervention over another. These include impact on physical function, quality of life (both psychological and social aspects), tolerability, convenience, availability, physician’s preference and experience, cost, and alternative treatment options . This review focuses on the determination of the clinical importance of changes in pain intensity (PI), usually the primary outcome measure in clinical trials of these conditions.
Ultimately, this review should help those who generate the metrics of clinically important changes, and those who use these metrics to make informed decisions regarding orthopedic treatments. To this end, we will review how these metrics are generated, and how these metrics can and should be interpreted to make informed decisions, highlighting the many pitfalls of these two processes.
Overview of the process
In determining whether an intervention studied in an RCT has produced a clinically important benefit, two different processes are involved (Figure 1). The first is to determine what magnitude of change in PI is considered clinically important in the relevant treatment population. To accomplish this goal, one needs to collect data from clinical trial evaluating treatments for pain in the specific condition (1a) and these data need to be analyzed to determine which changes in pain are considered clinically important. For example, one can determine through this process that a decrease in pain of 20 mm on the 0–100 mm visual analog scale (VAS) in a patient with knee osteoarthritis (OA) is a clinically important change.
The second process consists of using the metrics determined in the first process as a yardstick to determine whether a treatment has produced a clinically important change in a particular patient. For instance, an OA patient who has a decrease in pain of 30 mm on VAS after treatment is considered to have a clinically important response (as determined in the first process), i.e., the patient is considered as a responder to the treatment. Whether the treatment produces a clinically meaningful impact is then determined by comparing the proportion of “responders” on active treatment compared to control.
Metrics of clinically important changes
The most widely used metrics of clinical important changes are described and defined in Table 1. They are typically generated by determining longitudinal improvement, i.e., comparing treatment outcome from pre- to post-treatment.
How do these metrics fit together? If the MDC on a pain scale was determined to be 20 units, the minimum clinically important difference (MCID) threshold 30 units, and the clinically important difference (CID) 45 units, this means that the pain scale cannot detect changes below 20 units, the minimum change in pain score considered clinically important by patients is 30 units, and the change in pain score considered clinically important is 45 units (Figure 2).
Calculating the SDD, MCD, MCID, and CID
To determine MCID in painful disorders, one needs to first collect clinical trial data with a pain endpoint. The clinical data used to make determinations of the smallest detectable difference (SDD)/MCID/CID should be as similar as possible (same population, same pain endpoint, similar treatment if applicable, similar study design) as the trial in which the MCID is used as a yardstick. This is because many factors can influence the effect size—and therefore the MCID—in a clinical trial.
First, as expected, the MCID is specific to the pain measure and scale used: an MCID calculated using 0–100 mm VAS pain is not equal or convertible to an MCID using the 0–10 numerical rating scale (NRS). Therefore, to determine whether the decrease in PI in a trial has reached the MCID, one needs to compare the trial results with MCID values calculated with the same pain scale. Tables 2 and 3 provide the MCID values calculated for different pain scales in different publications.
Interestingly, the MCID does not depend on the type of treatment [11,12,23]. For instance, the MCID on VAS for pain was ~25 mm in OA patients regardless of treatment (NSAIDs, THR, TKR, or rehabilitation) , i.e., improvement is improvement regardless what produced it.
MCID may not be the same across diseases unless this has been demonstrated. Stauffer et al.  found that the MCID in VAS pain is different between patients with knee OA, hip OA, and back pain, while Farrar et al.  found similar MCID for pain NRS in patients in OA, painful diabetic, neuropathy, postherpetic neuralgia, low back pain, and fibromyalgia.
The MCID also varies with the severity of the disease: the MCID is larger at higher baseline pain levels, suggesting that patients with severe pain require a larger amount of pain relief to report being satisfied (Table 4) . This is corroborated by data from Quintana  and Farrar  (Table 2).
Calculating SDD and MDC
There are two methods of estimating SDD/MDC which are purely statistical : SDD is calculated using the limits of agreement method (a.k.a., the Bland and Altman method ) and MDC using the standard error of the mean (SEM). One problem with the SDD is that its value depends on the sensitivity of the statistical method used .
Calculating MCID or CID
There are four methods to calculate the MCID: consensus, anchor-based, distribution-based, or a combination of anchor- and distribution-based methods.
In the consensus method, a panel of expert is convened and each expert provides his/her best estimate of the MCID until a consensus is achieved. For instance, the consensus method was used to define a decrease in PI from a baseline of ≥20% (moderate improvement) as a MCID and a decrease of ≥30% or ≥50% as a CID . A ≥50% reduction in pain from the baseline corresponds to “very much improved” on the Patient Global Impression of Change (PGIC), providing a cross-validation of the consensus method . The main problem with the consensus method is that it is not based on the opinion of the patient.
In the anchor-based method, the pain scores are compared with an external, independent, face valid criterion (termed “anchor”) to determine a MCID in pain. The anchor is generally a questionnaire in which patients report their level of improvement, chosen based on its good reliability and validity. Examples of anchors include the PGIC, a “transition” question, the Patient Global Assessment (PGA) of treatment effectiveness (Tables 2 and 3). Using these anchors, MCID can be calculated for both improvement and worsening (most studies report the MCID for improvement in pain).
The anchor can be used to create a receiver operated characteristics (ROC) curve, a common approach for determining the performance of diagnostic tests. The ROC cutoff is the value for which the sum of % of false positives and false negatives is the smallest (as illustrated in Figure 3). Alternatively, the cutoff is the value for PI reduction that best predicts a specified change in the anchor (e.g., patients “much improved” on a PGIC). Tables 2 and 3 show examples of anchor-based calculations of MCID or CID in pain in OA (Table 2) and in painful spine conditions (Table 3).
Calculation of the MCID versus CID is based on the anchor threshold. Calculating the MCID is based on selecting patients with minimum improvement on the anchor, while calculating the CID is based on selecting patients with great improvement. For instance, Gum  defined the MCID for 0–10 NRS as the mean change in PI in patients reporting feeling “somewhat better” and the CID as the change in PI in patients “much better” (Table 3); with these cutoffs, patients with a decrease in back PI of ≥3.1 points on the 0–10 NRS can be considered as minimally improved (MCID), while those with a decrease in PI of ≥5.3 points can be considered greatly improved (CID) (Table 3).
There are several problems associated with anchor-based approaches. First, they are not suitable for conditions where most patients will improve and only a few remain unchanged. Second, they do not take into account the variability of the sample. The optimal cutoff is an average; some patients require smaller or larger changes in PI, for example, to feel “much improved.” Third, there are inherent problems associated with anchors for pain: (i) there is no objective measure of improvement in pain since pain is a subjective experience; (ii) the anchors used often measure “improvement,” which is a composite endpoint of pain and other factors, such as function; and (iii) patients may have difficulty to recall their initial status to accurately report their level of improvement between pre- and post-treatment. Finally, and most importantly, the degree of change in the anchor that is meaningful to patients is usually uncertain, defeating the purpose of the anchor.
Distribution-based methods use a statistical method to measure the variability of a variable (e.g., PI) within the sample and determine what degree of change in that variable is generally of clinical importance. One distribution-based approach uses the SEM: because the SEM value reflects the imprecision of the measurement, an MCID value below the SEM does not reflect a true change. Another distribution-based method is the MDC, where MDC is the smallest change above the measurement error. In this approach, the MCID value is defined as the upper value of the 95% confidence interval (CI) for the average change score in non-responders. The basis of using the SEM as MCID is supported by the fact that MCIDs often turn out to be around 1 SEM or ½ SD .
Distribution-based approaches have two important limitations. First, they allow calculation of the MCID, but not the CID. Second, they only define the minimum value below which a change in pain score is hopefully not due to measurement error.
Combination of anchor-based and distribution-based methods
One approach that combines both methods consists of (i) defining responders/non-responders using an anchor for improvement and then (ii) calculating the MCID based on the MDC: the MCID is then equal to the upper value of the 95% CI for the average change in pain score seen in non-responders with the anchor. Using this combined method, Parker et al. found a MCID of 2.6 points for neck pain on VAS, compared to 4.1 points for the ROC method ; the MCID for arm pain, however, was similar with both methods (4.1 vs. 4.0 points, respectively). Another way to do this is to use graphical method that integrates both anchor- and distribution-based approaches (see de Vet  for details). Using that approach, de Vet  found an MCID of 4 points on 0–10 NRS pain with the combined approach, versus 2.5 points with the ROC approach alone. Although the combined approach is more complex, it has the advantage over the pure anchor-based method of accounting for the variability of the sample.
Pitfalls with the calculation of the CID
The CID value is dependent on the methodology used to calculate it. One study used a variety of anchor-based (average change, change difference, and ROC) and combination (anchor + SEM or MDC) methods and found that the MCID could vary by seven- to eightfold for the same anchor depending on the method used (Table 4) . Another study that used four anchor-based or combination methods to calculate the MCID in pain in lumbar surgery found a wide range of MCID values, from 2.7 to 4.0 points for neck pain and from 2.4 to 4.2 points for arm pain on a 0–10 VAS . Finally, a study found that the distribution-based MDC method yielded MCID values ten times lower than an anchor-based method (0.20 and 0.23 points by MDC vs. 3.1 and 2.8 points by anchor for back and leg pain, respectively) (Table 3) . These studies clearly demonstrate that the MCID value is dependent on the method used to calculate it. However, this is not always the case, and some studies have shown that two different methods can yield similar MCID values ( [Table 2];  [Table 2];  [Table 3] for arm pain only).
The MCID calculation using the anchor-based method may also depend on the anchor type (PGIC, PGA, transition question, etc.). Various studies have compared the MCID values with two anchors (Tables 2 and 4). While in some instances, the anchor impacts the MCID ( [Table 2]), it has little effects in other cases ( [Table 2];  [Table 5]). Thus, the MCID cannot be assumed to be robust to different methods of calculation.
Finally, the CID value depends on the threshold of improvement. For instance, selecting patients “much improved” versus “very much improved” on PGIC (anchor) doubled the CID value from 2 to ≥4 points .
Using the MCID to determine treatment efficacy
Contextualizing the use of MCID as a yardstick
To appropriately use the MCID to determine the efficacy of a treatment in a trial, one must use MCID values that were calculated in a very similar context to the trial, i.e., for the same pain measure, in a similar patient population (pain condition, severity of disease at baseline, baseline characteristics), and using a similar trial design because the MCID is dependent on all these factors, as discussed above. In addition, one should be mindful of how the MCID was calculated, as many factors influence the MCID value, as discussed above (“Pitfalls in calculation and interpretation of clinically important differences” section). MCIDs values for a variety of pain measures, painful conditions, and patient populations have been calculated and published. To find the appropriate MCID yardstick to use among these publications, clinicians should search through publication databases using search words such as “MCID,” “pain,” accompanied with the treatment of interest (e.g., lumbar surgery), and the measurement of interest (e.g., VAS neck, back, or leg pain). Then, it requires sorting through these publications to find the most appropriate one (“Pitfalls in calculation and interpretation of clinically important differences” section). For instance, if one is interested in finding the MCID value for VAS neck pain in a population of patients undergoing anterior cervical discectomy and fusion, a type of search as described above retrieved a very appropriate article from Parker et al. , which shows an MCID value of 2.6 points.
Pitfalls in calculation and interpretation of clinically important differences
Pitfalls in generating efficacy data to calculate metrics of clinically important differences
Choice of pain measure: different pain measures yield different MCIDs
Efficacy in clinical trials is impacted by various factors (population characteristics, trial design)
Pitfalls in calculating the metrics of clinically important differences
The MCID value is impacted by:
The method used to calculate it (anchor, ROC, distribution)
The type of anchor chosen
The definition (threshold) of improvement
The population characteristics such as disease type and severity (baseline pain score)
Pitfalls in applying the metrics of clinically important differences to clinical trial data
The appropriate MCID value has to be found or calculated for the specific application
In clinical trials, the MCID yardstick should be applied to changes in individual subjects, not to group changes; applying individual CIDs on a group level is misleading
If the appropriate MCID value cannot be found, one approach is to calculate the MCID within the same clinical trial. In other words, the same clinical trial data serve to calculate the MCID value, which is then applied to each patient of the trial to determine which patient met the MCID threshold. For instance, a clinical trial of lumbar discectomy was used (i) to calculate the MCID of leg and back pain (3.5 and 2.5 points for leg and back pain, respectively, on 0–10 NRS) and (ii) to determine the proportion of patients with improved leg and back pain (i.e., patients with pain scores above the MCID) . Using the ROC method, the authors found a MCID of 2.5 for NRS back and 3.5 for NRS leg; when applied to the trial data, the proportion of patients who had clinically significantly improvement (met the MCID) in leg pain and back pain was 67% and 59%, respectively.
Comparing the efficacy of two treatments in clinical trials
The MCID can be used to determine treatment efficacy or to compare the efficacy of two active treatments in clinical trials. To do so, first, one has to calculate the proportion of patients in each treatment group that meet the MCID, defined as individual patients for whom the difference between pre- versus post-treatment pain score is equal to or greater to the MCID threshold. Then, the treatment groups can be compared for the proportion of patients who meet the MCID using a standard statistical method. For instance, a study evaluating transsacral axial interbody fusion found that only 50% of patients met the MCID of the VAS score for back pain . Another study evaluating lumbar spine surgery found that 67% of patients met the MCID of leg pain .
One important error that is made when determining treatment efficacy in clinical trials is to calculate the mean difference (pre- versus post-treatment) pain score for the treatment group and comparing it to the MCID (“Pitfalls in calculation and interpretation of clinically important differences” section). The MCID is a metric that is based on longitudinal differences in individual patients and should be used in the same context.
Although this seems straightforward, the clinical trial data used to calculate the MCID have a few issues that are inherent to all analgesic trials: (i) analgesics that are known to be effective only result in an average decrease in PI scores of 0.5 to 1 point on a 0–10 NRS compared to placebo, which means that MCID values tend to be small (10–20 mm on VAS, Table 2); (ii) the proportion of responders (patients whose PI decreases by ≥30%) is often 40% to 50% for effective analgesics, which means that the % of patients who meet the MCID should be relatively low; (iii) the placebo effect is often high, leading to a situation whereby known effective analgesics frequently demonstrate non-significant effects compared to placebo (failed trials); and (iv) pain is a subjective experience and pain reporting by patients may vary according to patient characteristics and study design or conduct, affecting the pain endpoint and therefore the % patients who meet the MCID.
Determining treatment efficacy in individual patients
The SDD/MDC and MCID can be used by orthopedic practitioners in the clinical setting to determine whether an individual patient has responded to treatment based on the patient’s change in pain score between pre- versus post-treatment. Figure 2 provides examples of three different cases with different response to a treatment. Categorizing patients by level of response to treatment should help physicians make further treatment decisions for patients (continue or change treatment) and make treatment decisions for other patients with a similar condition.
There are important caveats to applying the MCID, which is determined in clinical trial, to the clinical setting (“Pitfalls in calculation and interpretation of clinically important differences” section). First, the MCID is derived in a homogeneous population in clinical trial, while patients in the clinical setting are heterogeneous. Second, categorizing patients as responder/non-responder can negatively affect patient management as it does not take into account the category of patients who are borderline responders or poor responders. For these suboptimal responders, making an appropriate treatment decision will require additional clinical information regarding treatment effect.
One key problem in using the MCID in the clinical setting is that patients may not have clinically important changes in pain but may have substantial improvements in function, sleep, or other clinical benefits. Thus, applying only MCID in painful orthopedic indications where function and other outcomes are important to make treatment decisions may not be the best approach, i.e., may have negative implications for patient management. Other domains including physical functioning, emotional functioning, and overall improvement, for which an MCID can be calculated, should be considered. Adverse effects, burden to patient, and cost should also be taken into consideration when making treatment choices (“Pitfalls in calculation and interpretation of clinically important differences” section).
Using the MCID to inform guidelines
The MCID (or minimal clinically important improvement (MCII)) derived from clinical trials is used to inform guidelines. For example, in the OA treatment guidelines , clinical significance takes into account both the statistical significance of the treatment efficacy (versus placebo) and the 95% CI of the mean pain score relative to MCII (Table 6) to flag as ineffective treatments whose upper bound estimate of treatment efficacy remains below the MCII threshold.
The use of the MCID or MCII as the cornerstone to determining treatment efficacy in guidelines has many caveats . First, the MCID calculation can greatly vary between studies, making the comparison between treatments assessed in different studies very difficult. Second, many clinical variables (disease severity, age, body weight, activity level, comorbidities, and prior treatments) not reflected in the MCID are important to consider when selecting a treatment for a patient. Thus, the MCID should only be considered as a tool to analyze clinical trial results that supplements, but does not replace, expert clinical judgment to make decisions when treating patients with orthopedic conditions.
The MCID and CID are useful tools to determine whether a treatment produces clinically meaningful effects in a patient. However, these metrics have many pitfalls, requiring a good understanding of the methods to calculate them and their context of use. Orthopedic surgeons that will use these metrics need to carefully understand them and be aware of their pitfalls.
Pham T, Der Heijde DV, Lassere M, Altman RD, Anderson JJ, Bellamy N, et al. Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria. J Rheumatol. 2003;30:1648–1654
Morley S, Williams AC. Conducting and evaluating treatment outcome studies. In: Turk DC, Gatchel RJ, editors. Psychological approaches to pain management: a practitioner’s handbook. 2nd ed. New York: Guilford; 2002.
Copay AG, Subach BR, Glassman SD, Polly Jr DW, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J. 2007;7:541–6.
Kane RC. The clinical significance of statistical significance. Oncologist. 2008;13:1129–33.
Man-Son-Hing M, Laupacis A, O'Rourke K, Molnar FJ, Mahon J, Chan KB, et al. Determination of the clinical importance of study results. J Gen Intern Med. 2002;17:469–76.
Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain. 2009;146:238–44.
Wells G, Beaton D, Shea B, Boers M, Simon L, Strand V, et al. Minimal clinically significant important differences: review of methods. J Rheumatol. 2001;28:406–12.
Jaeschke R, Singer JA, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407–15.
Beaton DE, Bombardier C, Katz JN, Wright JG, Wells G, Boers M, et al. Looking for important change/differences in studies of responsiveness. OMERACT MCID working group. Outcome measures in rheumatology. Minimal clinically important difference. J Rheumatol. 2001;28:400–5.
Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheumat Dis. 2005;64:29–33.
Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–58.
Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seidenberg BC, Bellamy N. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities Osteoarthritis Index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol. 2000;27:2635–41.
Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum. 2001;45:384–91.
Escobar A, Quintana JM, Bilbao A, Aróstegui I, Lafuente I, Vidaurreta I. Responsiveness and clinically important differences for the WOMAC and SF-36 after total knee replacement. Osteoarthritis Cartilage. 2007;15:273–80.
Quintana JM, Aguirre U, Barrio I, Orive M, Garcia S, Escobar A. Outcomes after total hip replacement based on patients’ baseline status: what results can be expected? Arthritis Care Res. 2012;64:563–72.
Escobar A, García Pérez L, Herrera-Espiñeira C, Aizpuru F, Sarasqueta C, Gonzalez Sáenz De Tejada M, et al. Total knee replacement; minimal clinically important differences and responders. Osteoarthritis Cartilage. 2013;21:2006–12.
Carreon LY, Bratcher KR, Canan CE, Burke LO, Djurasovic M, Glassman SD. Differentiating minimum clinically important difference for primary and revision lumbar fusion surgeries. J Neurosurg Spine. 2013;18:102–6.
Gum JL, Glassman SD, Carreon LY. Clinically important deterioration in patients undergoing lumbar spine surgery: a choice of evaluation methods using the Oswestry Disability Index, 36-Item Short Form Health Survey, and pain scales: clinical article. J Neurosurg Spine. 2013;19:564–8.
Carreon LY, Glassman SD, Campbell MJ, Anderson PA. Neck Disability Index, short form-36 physical component summary, and pain scales for neck and arm pain: the minimum clinically important difference and substantial clinical benefit after cervical spine fusion. Spine J. 2010;10:469–74.
Copay AG, Glassman SD, Subach BR, Berven S, Schuler TC, Carreon LY. Minimum clinically important difference in lumbar spine surgery patients: a choice of methods using the Oswestry Disability Index, Medical Outcomes Study questionnaire Short Form 36, and pain scales. Spine J. 2008;8:968–74.
Solberg T, Johnsen LG, Nygaard ØP, Grotle M. Can we define success criteria for lumbar disc surgery?: estimates for a substantial amount of improvement in core outcome measures. Acta Orthop. 2013;84:196–201.
Parker SL, Godil SS, Shau DN, Mendenhall SK, McGirt MJ. Assessment of the minimum clinically important difference in pain, disability, and quality of life after anterior cervical discectomy and fusion: clinical article. J Neurosurg Spine. 2013;18:154–60.
Stauffer ME, Taylor SD, Watson DJ, Peloso PM, Morrison A. Definition of nonresponse to analgesic treatment of arthritic pain: an analytical literature review of the smallest detectable difference, the minimal detectable change, and the minimal clinically important difference on the pain visual analog scale. Int J Inflam. 2011;2011:231926.
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–10.
Lassere M, Boers M, van der Heijde D, Edmons J, Saudan A, Verhoeven AC. Smallest detectable difference in radiological progression. J Rheumatol. 1999;26:731–9.
Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105–21.
Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582–92.
de Vet H, Ostelo R, Terwee C, van der Roer N, Knol DL, Beckerman H, et al. Minimally important change determined by a visual method integrating an anchor-based and a distribution-based approach. Qual Life Res. 2007;16:131–42.
Hofstetter CP, Shin B, Tsiouris AJ, Elowitz E, Härtl R. Radiographic and clinical outcome after 1- and 2-level transsacral axial interbody fusion: clinical article. J Neurosurg Spine. 2013;19:454–63.
American Academy of Orthopaedic Surgeons (AAOS). Treatment of osteoarthritis of the knee evidence-based guideline, 2nd edition; Adopted by the American Academy of Orthopedic Surgeons Board of Directors. May 18, 2013.
Bannuru RR, Vaysbrot EE, McIntyre LF. Did the American Academy of Orthopaedic Surgeons osteoarthritis guidelines miss the mark? Arthroscopy. 2014;30:86–9.
The authors declare that they have no competing interests.
NK is the owner and FP is a contractor of Analgesic Solutions, a for-profit company providing consultant services to the pharmaceutical industry. All authors significantly and equally contributed to the manuscript. All authors have read and approved the final manuscript.
The authors received financial support from Depuy Synthes to support independent writing of this review.
About this article
Cite this article
Katz, N.P., Paillard, F.C. & Ekman, E. Determining the clinical importance of treatment benefits for interventions for painful orthopedic conditions. J Orthop Surg Res 10, 24 (2015) doi:10.1186/s13018-014-0144-x
- Anchor-based methods
- Distribution-based methods
- Orthopedic surgery